Clinical trial · Expanded Access
Flotetuzumab Expanded Access Program
An Expanded Access Program Providing Flotetuzumab in the Treatment of Acute Myeloid Leukemia Patients in Single, Individually-approved Patients
NCT04678466CI-TRIAL-00058785no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the Expanded Access program is to provide flotetuzumab to patients with acute myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| AML, Adult Recurrent | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| flotetuzumab | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Weight of at least 17 kilograms * CD123-positive hematologic malignancy * Adequate organ reserve * Provider and site are trained on study protocol using flotetuzumab Exclusion Criteria: * AML that meets inclusion criteria for study CP-MGD006-01 (NCT02152956) * Primary induction failure * Early relapse (less than 6 months after first complete remission ) * Three prior lines of therapy, including maximum of 1 prior salvage attempts
References
Publications (0)
Data not yet available
No reference posted for this study.